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An occasional patient with Cushing's syndrome may re- 
quire urgent management primarily because the chronic 
ravages of hypercortisolism have caused the patient to be in 
a precarious metabolic condition. The side effects of pro- 
longed excess corticosteroids increase the risk of operations 
in such patients and must be considered in overall manage- 
ment. Among the many effects of hypercortisolism to be 
considered are hypertension, diabetes, ocular hyperten- 
sion, myopathies, dermatologic changes including skin 
infection, pancreatitis, osteoporosis, pathological fractures, 
peptic ulcers, renal calculi, coagulopathies, hypokalemia, 
poor wound healing, and increased susceptibility to infec- 
tion. The most effective way to avert these complications is 
by earlier diagnosis and definitive treatment of Cushing's 
syndrome. The present report includes a review of the 
etiology and diagnosis of Cushing's syndrome and the 
management of problems associated with hypercortisolism. 
Hypercortisolism producing Cushing's syndrome is 
not generally considered as a condition requiring 
emergent surgical management. However, patients 
with untreated or unrecognized Cushing's syn- 
drome may present with overwhelming, uncon- 
trolled infection, acute psychosis, pituitary apo- 
plexy associated with acute adrenal insufficiency, 
or with a concomitant disease requiring emergent 
surgical intervention. An occasional patient with 
Cushing's syndrome may require urgent manage- 
ment primarily because the chronic ravages of 
hypercortisolism have caused the patient to be in a 
precarious metabolic condition. The side effects of 
prolonged excess corticosteroids increase the risk 
of operations in such patients and must be consid- 
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ered in overall management. Among the many 
effects of hypercortisolism to be considered are 
hypertension, diabetes, ocular hypertension, myop- 
athies, dermatologic changes including skin infec- 
tion, pancreatitis, osteoporosis, pathological frac- 
tures, peptic ulcers, renal calculi, coagulopathies, 
hypokalemia, poor wound healing, and increased 
susceptibility to infection [I-4]. 
The most effective way to avert these complica- 
tions is by earlier diagnosis and definitive treatment 
of Cushing's syndrome. This paper will, therefore, 
review the etiology and diagnosis of Cushing's 
syndrome and then consider the management prob- 
lems associated with hypercortisolism. 
Cushing's  S y n d r o m e  
Etiology 
The most common cause of Cushing's syndrome is 
the excessive administration of exogenous gluco- 
corticoids. Iatrogenic Cushing's syndrome may be 
associated with any or all of the complications that 
may be seen in patients with endogenous overpro- 
duction of cortisol [4]. The diagnosis should be 
readily apparent by physical examination and an 
adequate history. 
In the 50 years since Cushing's classic descrip- 
tion of the clinical manifestations of pituitary baso- 
philism, much new knowledge about the syndrome 
has accumulated [5]. The most common primary 
condition causing hypercortisolism is now known to 
be bilateral adrenal hyperplasia due to excess 
ACTH and accounts for approximately 80% of all 
cases [3-13]. A pituitary tumor, usually a basophilic 
adenoma, is the source of ACTH adrenal stimula- 
tion in 65% of patients with the syndrome. Only 
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15% of pituitary tumors causing Cushing's disease 
were detected when only conventional skull roent- 
genographic studies were used. Even with sophisti- 
cated imaging procedures, some microadenomas 
may not be identified. They may remain undetected 
until the pituitary gland has been explored by 
modern microsurgical techniques. In approximately 
5% of the patients, the excess secretion of ACTH 
by the pituitary will not be associated with an 
adenoma. It is currently believed that in this group 
of patients, a neurohypothalmic disturbance causes 
the CRF/ACTH regulatory mechanism to function 
improperly. A non-pituitary, ectopic, or paraendo- 
crine source of ACTH is the cause of Cushing's 
syndrome in about 10% of all cases [14, 15]. 
Cushing's syndrome results from a functioning 
adrenal neoplasm in 20% of all cases. One-half of 
these tumors are adenomas, whereas the others are 
corticocarcinomas that have maintained sufficient 
endocrine function to produce excessive amounts 
of steroids. Functioning adrenal tumors secrete 
autonomously and inhibit the normal production of 
ACTH, resulting in suppression and atrophy of the 
contralateral adrenal gland [16, 17]. 
Diagnosis 
Usually, the physical stigmata of Cushing's syn- 
drome are present at the time of diagnosis. These 
include truncal, head, and neck obesity; plethora; 
hirsutism; hypertension; proximal muscle weakness 
and wasting; atrophic skin; purple striae; bruises; 
and acne of the face and trunk. Additional features 
frequently include amenorrhea, osteoporosis, glu- 
cose intolerance, and mental disturbance. The hy- 
pertension of Cushing's syndrome is attributed to 
chronic hypervolemia and is usually not severe. An 
occasional patient, however, may develop conges- 
tive heart failure or suffer a cerebrovascular acci- 
dent as a late complication of the disease. When 
Cushing's syndrome is of rapid onset and severe, 
weight loss and pronounced generalized muscle 
wasting may be the predominant clinical features. 
This is most likely to occur in patients with malig- 
nant paraendocrine tumors producing ACTH. 
The therapy of Cushing's syndrome requires that 
a specific etiologic diagnosis be determined. First, it 
must be established that the patient has Cushing's 
syndrome (Table 1). A loss of the normal diurnal 
pattern of cortisol secretion by the adrenal glands 
occurs in all cases. A simple screening test to make 
this determination is the single-dose overnight dex- 
amethosone suppression test. If there is suppres- 
sion of the 8-A.M. cortisol level, Cushing's syn- 
drome can be ruled out. Because suppression may 
not occur in a number of patients who do not have 
Cushing's syndrome, the 2-rag dose dexamethosone 
test is performed as a more definitive study. Once it 
has been established that a patient does have Cush- 
ing's syndrome, a more precise etiologic diagnosis 
is determined by plasma ACTH levels, high-dose 
dexamethosone suppression, and metyrapone tests. 
These tests will determine whether the hypercorti- 
solism is pituitary ACTH dependent, due to ectopic 
ACTH, or caused by an autonomously secreting 
corticoid neoplasm (Table 2) [3, 6, 18]. 
Most pituitary adenomas causing Cushing's dis- 
ease are too small to be detected by radiological 
techniques formerly used, including angiography 
and pneumoencephalography. Computed tomogra- 
phy (CT) has replaced multidirectional tomography 
as the imaging procedure of choice in preoperative 
evaluation of those patients without obvious en- 
largement of the pituitary fossa. CT sections 2 mm 
or less with coronal-sagittal reconstruction allow 
for precise visualization of bony structures of the 
pituitary fossa and sphenoid sinus. Also, the cav- 
ernous portion of the carotid artery, cavernous 
sinus, pituitary gland with microadenoma, and su- 
prasellar cistern can all be seen on one examination 
[8, 13, 17, 19, 20]. 
Treatment 
Thirty years ago patients with Cushing's disease 
were frequently treated by bilateral adrenalectomy 
[9]. Patients with demonstrated pituitary tumors 
were treated with hypophysectomy or pituitary 
radiation therapy. The recognition of the high inci- 
dence of pituitary microadenomas has, however, 
resulted in a revolutionary change in the manage- 
ment of Cushing's syndrome in recent years. Cur- 
rently, the most popular definitive treatment of 
Cushing's disease in which a basophilic ACTH- 
secreting adenoma is assumed or proven to be 
present, is the transsphenoidal microsurgical tech- 
nique. It is a therapeutically successful procedure 
with minimal morbidity and mortality when per- 
formed by a skilled neurosurgeon and considered 
the treatment of choice in many centers [7, 8, I0, 
12, 13, 20]. Bilateral adrenalectomy with radiation 
therapy to the pituitary remains as an effective 
alternative therapy [9, 21]. External irradiation of 
the pituitary from conventional sources, as a defini- 
tive treatment, has largely been abandoned because 
it was frequently ineffective and was associated 
with delayed remissions of from 6 to 18 months 
even when a response did occur. Newer techniques 
including closed stereotactic radiosurgery, intersti- 
tial irradiation, and proton beam irradiation are 
currently being evaluated and may prove to be 
satisfactory alternatives to surgical therapy. One of 
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Table 1. Screening tests for Cushing's syndrome. 
Test Method Normal Cushing' s syndrome Comments 
Plasma cortisol Blood sample 
(A.M./P.M.) 






2 mg low-dose dexa- 
methasone sup- 
pression 
24-hour urine collec- 
tion 
24-hour urine collec- 
tion 
Administer 1 mg 
dexamethasone 
orally at midnight. 
Measure A.M. plas- 
ma cortisol 
Administer 0.5 mg 
dexamethasone 
orally every 6 h for 
2 days. Measure 
24-hour urinary 17- 
OH steroids 
A.M. 3-34 Ixg/100 ml 
P.M. 0-22 txg/100 ml 
--< 108 ixg/day 
3-7 mg/day/g urine 
creatinine 
<3.5-10 ixg/100 ml 
(depending on as- 
say method) 
<2.5 mg/24 h/g urine 
creatinine 
Loss of A.M. and 
P.M. variation; ele- 
vated 
Elevations > 108 ixg/ 
day 
>9 mg/day/g urine 
creatinine 
No suppression. Lev- 
els >3.5-10 p~g/100 
ml 




values. Loss of 
variation in acutely 
ill and alcoholic pa- 
tients 
Useful screen when a 
reliable 24-hour 
urine can be ob- 
tained. Few false- 
positives and false- 
negatives 
Much overlap be- 
tween normal and 
Cushingoid patients 
and those with 
Cushing's disease 
Low incidence of 
false-negatives. 
False (-+)'s in pa- 
tients on dilantin or 
estrogens 
Definitive diagnostic 
test for Cushing's 
syndrome 
Table 2. Tests to determine etiology of Cushing's syndrome. 
Adrenal Pituitary Ectopic Nodular 
Test Method adenoma adenoma ACTH hyperplasia Comments 
High-dose dexa- Obtain baseline Nearly all Nearly all No suppres- No suppres- 
methasone sup- 24-hr urine 17- patients patients sion in sion in 
pression OH steroids, fail to do sup- 75% of pa- most pa- 
Administer 2 suppress press to tients. Tu- tients 
mg dexametha- to 40% 40% mors may 
sone orally ev- baseline baseline exhibit cy- 
ery 6 h for 2 clic hor- 
days. Measure monogene- 
24-h urine 17- sis 
OH steroids on 
second day of 
test 
Plasma ACTH Blood sample Low or Normal or Normal or Normal, ele- 
levels by RIA unde- elevated elevated vated or 
tectable low levels 
Metyrapone test Administer 750 Fall in uri- Increase in About V2 of About 1/2 of 
mg metyrapone nary 17- 17-OH patients patients 
orally every 4 h OH ste- steroid will show will show 
for 6 doses. Ob- roid excre- an increase an increase 
tain urinary 24 h excre- tion (small (sample 
17-OH steroids tion sample tested is 
day before, day tested) small) 
of, and day af- 
ter metyrapone 




itary causes of 
Cushing's syn- 
drome 
Important to de- 
termine adrenal 
adenoma vs. ec- 
topic ACTH 
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the real drawbacks to bilateral adrenalectomy, in 
addition to the critical need for life-long replace- 
ment therapy, is the development of Nelson's syn- 
drome in 20-40% of long-term surviving patients 
[22, 23]. This complication can be decreased by 
pituitary irradiation, but some patients eventually 
develop enlarging pituitary tumors and show the 
stigmata of excess ACTH secretion. The most 
compelling reason to consider adrenalectomy is that 
the operation immediately cures hypercortisolism. 
One of the advantages of transsphenoidal pituitary 
microsurgery is that it can be performed in relative- 
ly poor risk patients. Another major advantage is 
that most patients do not require replacement thera- 
py permanently. 
Currently, bilateral adrenalectomy is reserved for 
those patients in whom other forms of therapy 
including drug, radiation, and/or transsphenoidal 
microsurgery have failed or when the severity of 
Cushing's syndrome requires urgent definitive cure. 
Another alternative to either surgery or pituitary 
irradiation for the definitive treatment of Cushing's 
disease is drug therapy with mitotane (Lysodren '~, 
or o,p'-DDD). This drug inhibits the biosynthesis of 
cortisol and, when administered long-term, de- 
stroys the cortical cells in the zona fasciculata. 
Schteingardt treated 36 patients at the University of 
Michigan with low doses of mitotane and achieved a 
remission in 29 patients that persisted after the drug 
was discontinued [11]. The failures of this therapy 
were eventually treated with either transsphenoidal 
microsurgery or bilateral adrenalectomy. 
Each of the previously mentioned therapeutic 
measures will continue to play some role in the 
management of Cushing's disease. Those patients 
with the severest metabolic derangements from 
advanced disease, presenting to a surgeon, may 
require bilateral adrenalectomy because the other 
acceptable alternatives have already failed. 
One additional indication for bilateral adrenalec- 
tomy is primary adrenal nodular hyperplasia, a rare 
disease of obscure etiology that usually occurs in 
young patients. In this disease, ACTH levels are 
either low or completely suppressed and even high- 
dose dexamethasone suppression of cortisol may 
not occur. Both CT scans and NP-59 scintiscans 
may show bilateral adrenal enlargement. Bilateral 
adrenalectomy is curative. Radiation therapy to the 
pituitary is not indicated in these rare cases. 
In patients with the ectopic ACTH syndrome 
producing Cushing's syndrome, the onset of disease 
may be very rapid. The presenting features typical 
of Cushing's syndrome are frequently absent. 
These patients often have pronounced generalized 
muscle wasting, weakness, and weight loss. They 
also have symptoms or findings from the primary 
neoplasm secreting ACTH. Unfortunately, 60% or 
more of such patients will have a highly malignant 
pulmonary neoplasm. The prognosis in these cases 
is poor, and usually complete resection of the 
primary neoplasm cannot be accomplished. Occa- 
sionally, radiation therapy or chemotherapy may be 
beneficial. When the primary tumor is an apudoma, 
surgical resection may be possible for cure. Cush- 
ing's syndrome has been associated with carcinoid 
tumors, medullary carcinomas of the thyroid, thy- 
momas, and less frequently islet-cell tumors of the 
pancreas. Even when these have not been cured by 
surgical resection, debulking procedures may be 
palliative and furthermore, some response may be 
obtained with further therapy directed to the pri- 
mary tumor using both radiation and/or chemo- 
therapy. Whereas ACTH levels have been reported 
to decrease in patients with metastatic disease who 
have undergone irradiation of their primary lesion, 
this should not be expected to be very effective in 
most cases. Bilateral adrenalectomy may be consid- 
ered in patients with unresectable primary tumors 
in whom the prognosis is fair to good. A trial of 
either metyrapone or o,p'-DDD should be attempt- 
ed first, however. If the response is good and the 
drug tolerated, bilateral adrenalectomy may be 
avoided. It is important to monitor closely any 
patient being treated by drug therapy with steroid 
levels and to be aware that severe metabolic de- 
rangements, especially hypokalemia, hypochlore- 
mic alkalosis, gastric ulceration, hypercalciuria 
with formation of renal calculi, psychosis, or over- 
whelming sepsis may occur if the response is not 
sufficient. Some patients who do not respond to 
medical therapy will require urgent bilateral adre- 
nalectomy after expeditious correction of electro- 
lyte and other metabolic abnormalities. 
Adrenal Neoplasms 
Although there is a confusing variety of therapeutic 
measures available for the treatment of Cushing's 
disease, there is no controversy about the treatment 
of hypercortisolism caused by an adrenal adenoma. 
Surgical excision through a unilateral posterior ap- 
proach through the bed of the 12th rib is curative. 
Furthermore, after a period of 3 to 6 months, the 
contralateral, suppressed adrenal gland recovers 
function and steroid replacement therapy may be 
withdrawn. A unilateral posterior approach is asso- 
ciated with less morbidity than an anterior transper- 
itoneal operation. This requires that the tumor be 
localized preoperatively. Lateralization can be ob- 
tained in nearly all patients by computed tomogra- 
phy. Important additional information, however, 
can be obtained from iodocholesterol or NP-59 
scintiscans. Characteristically, an adenoma will 
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show unilateral uptake, confirming that the tumor is 
benign. There will be no uptake on the contralateral 
suppressed side. In contrast, an adrenocortical car- 
cinoma causing Cushing's syndrome is incapable of 
sufficient NP-59 uptake for imaging. Therefore, the 
presence of bilateral nonvisualization of the adrenal 
glands in a patient with clinical and biochemical 
evidence of Cushing's syndrome is presumptive 
evidence of malignancy [24]. An anterior surgical 
approach is used in operations for patients with 
adrenocortical carcinoma. A curative procedure is 
attempted when feasible. Efforts are made to re- 
move as much tumor as possible even when distant 
metastases are present. The patient is then started 
on mitotane, 6 g per day, and tapered to a well- 
tolerated 2 g per day dose within several weeks. 
The lower dose is usually well tolerated and main- 
tained indefinitely. In a series of 23 patients with 
adrenal carcinoma treated at the University of 
Michigan, 6 patients who underwent resection of 
the primary tumor and/or local radiation therapy 
but received no chemotherapy survived for an 
average of only 10 months [17]. In contrast, 17 
patients who were treated with mitotane had a mean 
survival of 47 months. The longest survival times 
occurred in a group of patients who received mito- 
tane as adjuvant therapy before clinical evidence of 
metastases was noted and in those who were treat- 
ed with mitotane and repeated surgery for recurrent 
tumor. The mean survival for this group was 74 
months. Several patients treated with mitotane for 
pulmonary metastases experienced reduction in the 
size or disappearance of the lesions. With the 
improved survival of patients with adrenal carcino- 
mas who have received combined surgical and 
mitotane therapy, aggressive efforts to excise as 
much tumor as possible appear fully justified. If 
recurrence of tumor occurs after initial response, 
repeated debulking operations are indicated. 
Drug Management of Cushing's Syndrome 
Although drugs do not cause remission of Cushing's 
syndrome as rapidly as either pituitary microsur- 
gery or bilateral adrenalectomy, they have proven 
useful in preparing some patients for operation and 
more recently as definitive therapy in others [11, 
25]. The use of drugs requires a thorough under- 
standing of their mechanism of action, dose sched- 
ule, and side effects. Treated patients require care- 
ful clinical and biochemical assessment during ther- 
apy and careful supervision. The most commonly 
used drugs in the treatment of Cushing's syndrome 
and in replacement therapy will be considered in 
this section. Dosage schedules for these drugs are 
given in Table 3. 
Centrally Acting Drugs 
The purpose in using these drugs is an attempt to 
suppress secretion of ACTH by the pituitary gland. 
Theoretically, these drugs should be most effective 
in patients with a disorder of the CRF/ACTH regu- 
latory mechanism and in patients with Cushing's 
disease due to microadenomas [26-32]. 
Cyproheptadine, a serotonin antagonist, has been 
used with mixed results [26-28]. Its mechanism of 
action is believed to be the inhibition of CRF at the 
hypothalmic level, as this hormone's release is 
mediated by serotonin. In 3 patients treated by 
Krieger, cortisol levels returned to normal [27]. 
There was prompt, objective, and subjective clini- 
cal improvement, but the follow-up period was 
short. In one patient, symptoms recurred as soon as 
the drug was withdrawn. Other authors have noted 
similar responses and have concluded that this drug 
is not a substitute for surgery but may be useful in 
improving patients with Cushing's disease in prepa- 
ration for operation. 
Bromocriptine is a dopamine agonist. It activates 
dopaminergic cells in the pituitary and may inhibit 
pituitary ACTH secretion in some patients with 
pituitary-dependent Cushing's disease. It has prov- 
en effective in the treatment of prolactin- and 
growth hormone-producing adenomas, but its use- 
fulness in Cushing's disease remains to be proven 
[29, 30]. 
Enzymatic Inhibitor 
Metyrapone is one of two commonly used drugs in 
Cushing's syndrome that enzymatically inhibit the 
formation of cortisol by the adrenal cortex [18, 33- 
361. Its action is to inhibit selectively the hydroxyl- 
ation of 11-deoxycortisol to form cortisol. Because 
the biosynthetic process stops at the 11-deoxycorti- 
sol level, a steroid that does not inhibit ACTH 
secretion by the pituitary, a resultant increase in 
both plasma ACTH and urinary 17-hydroxycorti- 
costeroids will occur, providing the adrenal-pitu- 
itary axis is intact. This is the basis for the metyra- 
pone test used to determine the pituitary's capacity 
to secrete ACTH. When ACTH rises in a patient 
after receiving metyrapone, it is of pituitary origin. 
If it is being secreted by an ectopic tumor, there is 
no increase in plasma levels when this drug is given. 
This drug has been successfully used in the long- 
term medical management of Cushing's disease and 
for the preparation of patients undergoing either 
pituitary or adrenal operations for Cushing's syn- 
drome. Metyrapone administration usually causes 
remission within weeks or months in nearly all 
patients with Cushing's syndrome. Unpleasant side 
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Table 3. Dosages of major drugs used in Cushing's syndrome. 





0.25 g twice daily to 1.0 g 4 times 
a day, orally 
250 mg, 2-4 times daily, orally 
7.5-25 mg/day, orally 
0.5 mg/kg/day 
o,p'-DDD (mito- 2-12 g/day 
tane) 
Dose should reduce mean fluorogenic corticosteroid 
concentration to 11-14.5 p~g/100 ml [18] 
A high percentage of patients have adverse reac- 
tions which cause them to stop the drug [16] 
Has antihistamine, cholinergic, and sedative effects 
as well as anticholinergic ones; commonly pre- 
scribed as an antipruritic or antihistamine (Periac- 
tin) 
Requires 2-4 months to show full effect. Dose can 
be decreased, once suppression of cortisol has 
been demonstrated [19]. Steroids must be re- 
placed as adrenal secretion is suppressed 
effects when it is used chronically limit its use. 
Those include nausea and vomiting, skin rashes, 
acne, and hirsutism in women. It is currently used 
most frequently as an adjunct to pituitary irradia- 
tion, other drugs, or as preparation for operation 
[34]. 
Aminoglutethimide inhibits the first reaction of 
steroidogenesis, the conversion of  cholesterol to 
pregnenolone [33, 37]. It, therefore,  interrupts the 
production of both cortisol and aldosterone. It, too, 
has undesirable side effects, the most common 
being sedation. Currently, it is used most frequently 
in combination with metyrapone as palliative treat- 
ment for functional adrenal cortical carcinoma and 
in the preparation of  patients with Cushing's syn- 
drome for operation [38-41]. 
Adrenolytic Drugs 
Mitotane or o ,p ' -DDD is a byproduct  of  insecticide 
research [25]. The drug was noted to cause selective 
destruction of  the adrenal cortices in experimental  
dogs. Although the mechanism of  action has not 
been determined, its relatively selective attack 
upon both the normal and neoplastic adrenal corti- 
cal cells is well established. It causes necrosis of  the 
zona fasciculata initially, but when used for a 
prolonged period of  time can also destroy the zona 
reticularis. It has been the only drug that since its 
clinical introduction in 1960 has proven effective in 
patients with metastatic adrenocortical  carcinoma 
[16]. Side effects of the drug when used in high 
doses have severely limited its use. Low-dose  mito- 
tane therapy, however,  is better  tolerated and can 
be administered for prolonged periods [ l l ,  16]. It 
has been shown to be of  value in a high percentage 
of patients with pituitary ACTH-dependent  Cush- 
ing's disease when combined with pituitary irradia- 
tion [11, 25]. Permanent  remissions occurred in 
Table 4. Relative potencies of various glucocorticoids. 
Compound Equivalent dose 
Hydrocortisone (cortisol) 20 mg 
Cortisone 25 mg 
Prednisone 5 mg 
Prednisolone 5 mg 
Methylprednisolone 4 mg 
Dexamethasone 0.75 mg 
Betamethasone 0.6 mg 
some patients after prolonged use [11]. Recently,  
adjuvant mitotane chemotherapy has been shown to 
bring about prolonged survival of patients with 
nonmetastatic adrenal carcinoma [16]. The most 
common side effects of this drug are anorexia and 
nausea which occur  in nearly all patients. These 
symptoms are dose dependent  and tolerated by 
most patients when low-dose therapy is adminis- 
tered. Other effects include diarrhea, vomiting, 
memory loss, skin rash, gynecomastia,  arthralgia, 
and leukopenia [11]. The adrenolytic effects of  
mitotane occur  over  a 2-4-month period but may 
take as long as 16 months. Adrenal insufficiency 
occurs in responding patients. Consequently,  re- 
placement therapy with glucocorticoids should be 
administered as soon as a response has been dem- 
onstrated. When mitotane has been given for pro- 
longed periods, mineral corticoid replacement  ther- 
apy may also be necessary.  
Synthetic Corticosteroids 
The most common cause of Cushing's syndrome,  as 
was noted earlier, is iatrogenic and due to the 
excessive or prolonged administration of exogenous 
steroids. Either acute or chronic toxic effects may 
develop in these patients and withdrawal of  the 
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Table 5. Protocol for glucocorticoid withdrawal. 
Interval Observation Result Glucocorticoid and dose 
Variable Underlying disease Worsening of underlying 
disease 
Symptoms and signs of 
steroid withdrawal 
When < l0 p~g/100 mg 4 wk 8 A.M. plasma cor- 
tisol 
When > 10 ~g/100 mg 
4 wk to in- 8 A.M. 250 ixg/m When plasma cortisol 
definite ACTH test (co- increment < 6 txg/100 
syntropin) ml or maximum < 20 
ixg/100 ml or both 
4 wk to in- 8 A.M. 250 ixg/m When plasma cortisol 
definite ACTH test increment > 6 ixg/100 
ml and maximum > 
20 txg/100 ml 
Variable; gradual decrements of dose to 
biological equivalent of hydrocorti- 
sone 20 mg/day 
Raise dosage for flareup of disease; 
continue if disease is quiescent; sup- 
plement for stress 
Begin hydrocortisone 20 mg/day, then 
taper by 2.5 mg/day once/wk to 10 
mg q.A.M, and continue this dosage; 
supplement for stress 
Stop maintenance hydrocortisone; sup- 
plement for stress 
Supplement for stress 
Stop supplementation for stress 
From Byyny R.L: Withdrawal from glucocorticoid therapy. N. Engl. J. Med. 295:30, 1976 [44]. 
drugs may become necessary. A variety of synthet- 
ic corticosteroids are widely used clinically. Indi- 
vidual compounds have considerable differences in 
potency and anti-inflammatory and glucocorticoid 
effects [42]. The relative potencies of commonly 
used steroids as compared to hydrocortisone are 
shown in Table 4. When administered in doses 
greater than the equivalent of 25-30 mg of hydro- 
cortisone per day, any of these drugs can suppress 
the pituitary secretion of ACTH and eventually 
cause adrenocortical atrophy [43]. The degree of 
ACTH and adrenal suppression is related to the 
particular compound, dosage, frequency of dosage, 
plasma half-life, and route of administration. Com- 
pounds having a longer half-life have greater ability 
to suppress ACTH and probably have a greater 
potential for producing adrenal atrophy [42]. A 
regimen for steroid withdrawal is shown in Table 5. 
This schedule is predicated on the fact that the 
pituitary precedes the adrenal gland in recovering 
from withdrawal following steroid suppression, and 
that the adrenal recovery is associated with re- 
newed responsiveness to challenge with ACTH 
[44]. Steroid-induced adrenal atrophy cannot be 
overcome by using ACTH, for reasons that are not 
entirely understood. It has been observed that when 
ACTH is used in patients after steroid withdrawal, 
its discontinuance results in return of the adrenals 
to an atrophic state [45]. Recovery gradually occurs 
over a period of months. 
Addisonian crisis, or acute adrenal insufficiency, 
can develop in any patient inadequately treated 
following the withdrawal of steroids and in any 
patient treated for Cushing's syndrome with drugs, 
operation, or radiation therapy who becomes inca- 
pable of producing an adequate daily amount of 
cortisol. Acute pituitary insufficiency may be the 
cause when there is hemorrhage into a pituitary 
tumor causing edema or infarction. This complica- 
tion can occur spontaneously but has also been 
reported after irradiation and o,p'-DDD therapy. 
Symptoms can range from mild meningeal irritation 
to severe headache, visual impairment, blindness, 
opthalmoplegia, cerebral infarction, and cardiovas- 
cular collapse. Treatment of acute adrenal insuf- 
ficiency must be initiated immediately. A C T  scan 
can then confirm the diagnosis by demonstrating 
areas of hemorrhage within the tumor or areas of 
low density corresponding to areas of infarction. 
Following bilateral total adrenalectomy, patients 
require life-long daily replacement therapy with the 
equivalent of 25-35 mg of hydrocortisone in divided 
doses, with approximately 2/3 being administered in 
the morning and V3 late in the afternoon. Mineral 
corticoid replacement with 0.1-0.2 mg of fludro- 
cortisone is usually required as well as glucocorti- 
coid replacement therapy. An occasional patient 
may require as much as 1.0 mg daily of 9-alpha- 
flurocortisol to remain in good electolyte balance, 
however. In the post-adrenalectomy patient, an 
increase in steroid dose may be necessary for even 
minor stress and is critically important during major 
illnesses and operations. As a general guideline, 100 
mg of hydrocortisone every 8 hours should be 
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begun 8 hours prior to an operation and continued 
through the first postoperat ive day. Approximately 
1/2 of thi.~dose may be given every 8 hours on the 
second day and the dosage then tapered as tolerated 
to maintenance levels thereafter.  The schedule will 
vary depending upon the nature of  the surgical 
procedure and the patient 's  postoperat ive course. 
Because the intravenous route may not always be 
continuously reliable, it may be safer to administer 
the first day 's  replacement as cortisone acetate 
intramuscularly. Hydrocor t i sone may be given as 
an intravenous drip or intramuscularly as the hemi- 
succinate or phosphate compound.  
R 6 s u m 6  
I1 est possible qu 'un malade atteint de maladie de 
Cushing ait besoin d 'e t re  trait6 sans attente en 
raisons de troubles m6taboliques s6v~res dus aux 
effets nocifs de l 'hypercort isolisme chronique qui 
augmentent les risques op6ratoires et doivent 6tre 
pris en consid6ration avant tout traitement. I1 en e s t  
ainsi de l 'hypertension,  du diab6te, de l 'hyperten-  
sion intra-oculaire, des 16sions dermiques compren- 
ant l ' infection cutan~e, la pancr6atite, l 'ost6opor- 
ose, les fractures pathologiques, l 'ulc~re peptique, 
les calculs r6naux, les coagulopathies, l 'hypokali~- 
mie, la lenteur du processus de cicatrisation et 
l 'augmentation de la suceptibilit6 ~t l ' infection. 
Le meilleur moyen d '6viter  ces complications est 
de porter sans retard le diagnostic de maladie de 
Cushing et de la traiter radicalement d6s que le 
diagnostic est pos6. 
Le pr6sent rapport comporte  une revue de l'6tio- 
logie et du diagnostic de la maladie de Cushing ainsi 
que du traitement des probl6mes qui sont associ6s 
l 'hypercortisolisme. 
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